Summary: PBIT (Pipeline Builder for Identification of drug Targets) is an online webserver that has been developed for screening of microbial proteomes for critical features of human drug targets such as being non-homologous to human proteome as well as the human gut microbiota, essential for the pathogen's survival, participation in pathogen-specific pathways etc. The tool has been validated by analyzing 57 putative targets of Candida albicans documented in literature. PBIT integrates various in silico approaches known for drug target identification and will facilitate highthroughput prediction of drug targets for infectious diseases, including multi-pathogenic infections.
Introduction
Emergence of multi-drug resistant pathogens and multi-pathogenic infections has necessitated the identification of novel disease targets. The wet-lab approaches for target identification have the disadvantage of being intensive on cost, manpower and time. This can be substantially overcome by supplementing the workflow with insilico methods for target identification/prediction. Curated information on sequences, structures, pathways, gene ontologies, drug-like compounds, essential genes and virulence factors available in online databases such as UniProtKB, KEGG (Kanehisa et al., 2016) , DrugBank (Law et al., 2014) , DEG (Luo et al., 2014) etc. can facilitate automated methods for identification of targets. Using subtractive genomics, that involves identification of microbial proteins that are non-homologous to human genes and are essential for the survival of the pathogen; putative drug targets have been successfully identified for many pathogenic bacteria (Anishetty et al., 2005) . Apart from being non-homologous to humans and essential for the organism, few other criteria to be considered are participation in metabolic pathways distinct from humans, non-homologous to human gut microbiota, druggability status, etc. Microbial proteins involved in multiple pathways, unique to the pathogenic organism are better targets than proteins involved in specific pathways. Targeting specific pathways may enhance development of multidrug resistance among pathogenic bacteria and should therefore be avoided (Shanmugham and Pan, 2013) .
Gut microbiota play a vital role in maintaining health by providing resistance to colonization of pathogens and opportunistic bacteria. Interactions of the drug with gut microbiota are therefore one of the major causes of toxicity and reduced bioavailability of the drug. This necessitates the filtering out of microbial proteins that share structural similarity with human gut flora proteome in the target identification workflow (Muhammad et al., 2014; Raman et al., 2008) .
Another important factor for a protein to be qualified as a drug target is its ability to bind to a drug-like molecule, also known as druggability. Not all proteins have structural characteristics conducive for drug-binding. Whole genome analyses estimates only 10% of genome as druggable, which emphasizes the significance of analyzing druggability for identification of target molecules (Radusky et al., 2015) . Druggability can be screened by mining online databases such as DrugBank and Therapeutic Target Database (TTD; Yang et al., 2016) that house information on known drug targets. The druggability screen has been found to reduce the output of a target discovery pipeline by 65% (Damte et al., 2013) . In spite of these well-established theories for target identification, researchers do not have an online algorithm/webserver that integrates these in silico approaches for screening the proteome of interest for potential drug targets. PBIT is an online pipeline builder tool for researchers to effortlessly customize and integrate various established concepts that exist for drug target identification.
Functionality
PBIT was developed using PHP (v5), HTML, PERL (v5.20), BioPERL and BLASTþ 2.4.0 executables. The server is hosted on Apache 2.4 webserver.
A brief description of the use of various modules available in PBIT is described below:
2.1 Specificity analysis 2.1.1 Non-homology analysis against human proteome This module helps to filter out sequences that share high sequence similarity with human proteome (UP000005640). The sequence similarity of the input sequences to the human proteome is computed using BLAST.
Non-homology analysis against human anti-targets
Proteins that trigger hazardous side effects under the influence of a drug are termed as 'anti-targets'. This module helps to screen out sequences that show significant sequence similarity to known human anti-targets.
Non-homology analysis against human gut flora proteomes
This module helps to screen out sequences that share high sequence similarity with human gut microbiota. The gut microbiota has an important role in maintaining the homeostasis and health of the individual.
It is to be noted that dissimilar sequences may share significant structural similarity which could contribute to cross-reactivity of drugs. Hence sequence-based screening may not identify such offtargets. Nevertheless, sequence-based screening has the advantage of screening several sequences whose structural information is lacking and is computationally less intensive.
Essentiality and virulence analysis
A potential target should be either indispensable for the survival of the pathogen and/or contribute to its virulence. This module helps to identify sequences that share high sequence similarity with the essential genes and/or virulence factors known for the organism. DEG (Database of Essential Genes) was used as the source of essential genes. VFDB (Virulence Factor Database; Chen et al., 2005) and DFVF (Database of Fungal Virulence Factors; Lu et al., 2012) were used as sources of virulent gene information for bacteria and fungi respectively.
Pathway analysis
Proteins that are involved in multiple, pathogen-specific pathways are optimal for designing highly potent drugs with reduced side-effects. This module helps in identifying the interaction pathways of the input sequences. Information on whether these pathways are also present in human are provided for the benefit of users. KEGG pathway database was used as a source of pathway information.
Broad spectrum analysis
This module helps to identify targets that have homologs in multiple pathogenic organisms. Identification of such targets is vital for development of broad-spectrum drugs for treatment of multiple infections or poly-microbial diseases. This analysis is executed by similarity search using BLAST against proteomes of 181 pathogenic organisms.
Druggability analysis
This module helps to screen druggable targets based on their sequence similarity to experimentally validated druggable targets. The sequence information for druggable targets were obtained from DrugBank database (Version 5) and Therapeutic Target Database (TTD).
Host-Pathogen Interaction
This module identifies targets that share sequence similarity to microbial proteins known to interact with human proteome (Mais et al., 2016) . The database for human anti-targets, human gut microbiota and list of pathogenic organisms were compiled from literature (Shanmugham and Pan, 2013, Raman et al., 2008) The PBIT webserver has been validated using Candida albicans, which is one of the major causes of opportunistic infections leading to Candidiasis in many immune-compromised patients. The fact that (i) the proteome of this organism is well characterized and (ii) intensive research has been carried out for identifying its drug targets; made C. albicans a good model for validating PBIT (Supplementary Information). PBIT proved to be a fast and efficient method to screen out potential targets of C. albicans using sequence information. It is expected that a further updated database on essential genes and virulence factors can enhance the prediction accuracy of PBIT.
